Brought to you by 
Novartis to buy NeuTec Pharma for £303.7mm
31 Jan 2008
Executive Summary
In its fifth deal in about a week's time, Novartis has now agreed to acquire public company NeuTec Pharma (anti-infectives for the hospital market) for £10.50 ($19.53) in cash per NeuTec share, for a total of £303.7mm ($568mm).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis to buy NeuTec Pharma for £303.7mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice